Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II HS-20106 in lower-risk MDS-associated anemia
ChiCTR2400090140Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Sep 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of elritercept in myelodysplastic syndrome (MDS) and anaemia (2 cohorts), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Proportion of subjects achieving IWG-revised HI-E within weeks 1 to 24. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
elritercept
03
Conditions
myelodysplastic syndrome (MDS)anaemia
Beyond the preview
Go deeper on ChiCTR2400090140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090140.